-
TCL, Panasonic expand participation in Via Licensing Alliance ATSC 3.0 patent pool, Korea Electronics Technology Institute brand new member
Read more: TCL, Panasonic expand participation in Via Licensing Alliance ATSC 3.0 patent pool, Korea Electronics Technology Institute brand new memberVia LA today welcomed TCL, already a long-term licensee, as a licensor, after Panasonic and the Korea Electronics Technology Institute also joined the pool as a licensee and licensor, respectively, earlier this month.
-
Pendulum swings back in favor of Fintiv in payment-system patent infringement dispute with Apple
Read more: Pendulum swings back in favor of Fintiv in payment-system patent infringement dispute with AppleThe United States Court of Appeals for the Federal Circuit has reversed a Western District of Texas grant of summary judgment in a dispute between Fintiv and Apple, reviving Fintiv’s infringement claims and remanding them for trial.
-
UPC Roundup (1 week): second medical use; evidence gathering through on-site experiments; various new cases
Read more: UPC Roundup (1 week): second medical use; evidence gathering through on-site experiments; various new casesThis is a summary of developments in and around the Unified Patent Court (UPC) in the week since our May 10, 2025 UPC Roundup. Only a few noteworthy things happened. 1. CoA: confidentiality concerns don’t warrant splitting up case In Corning v. Hisense, TCL and LG, Standing Judge (of the Court of Appeal (CoA)) Patricia Rombach affirmed…
-
Illumina sues Element Biosciences in Delaware over gene sequencing patents
Read more: Illumina sues Element Biosciences in Delaware over gene sequencing patentsWhile this is Illumina’s first official suit against Element Biosciences, the latter has already faced challenges over its gene sequencing technology based on prior art from Illumina’s assets.
-
Two U.S. pharma patent disputes fail to make it to trial: Alnylam concedes first round of litigation against Pfizer, BioNTech in COVID vaccine war, Nexus obtains summary judgment of invalidity
Read more: Two U.S. pharma patent disputes fail to make it to trial: Alnylam concedes first round of litigation against Pfizer, BioNTech in COVID vaccine war, Nexus obtains summary judgment of invalidityWhile Alnylam has dropped its patent infringement dispute against Pfizer, BioNTech, and Ingenus Pharmaceuticals has failed to take its cancer dispute to trial, both cases are subject to appeal.
-
10x Genomics and Bruker (NanoString) end global patent dispute
Read more: 10x Genomics and Bruker (NanoString) end global patent disputeThe UPC’s first major patent dispute has ended after the companies signed a global cross-license patent agreement.
-
New study: Huawei leads WiFi 7 SEP ownership, Ericsson sole European patentee
Read more: New study: Huawei leads WiFi 7 SEP ownership, Ericsson sole European patenteeA report on WiFi 7 SEP ownership published by GreyB today has found European patentees lag way behind those in Mainland China and the U.S., with Ericsson being the only patentee mentioned from the region.
-
UPC Dusseldorf issues first decision on second medical use, hands win to Amgen in cholesterol patent dispute against Sanofi
Read more: UPC Dusseldorf issues first decision on second medical use, hands win to Amgen in cholesterol patent dispute against SanofiThe Dusseldorf Local Division has clarified how the UPC deals with second medical use in patent infringement proceedings, including considering the extent or significance of the allegedly infringing use, and whether an entity is “positively” or “negatively” influencing a market by encouraging infringement, or preventing a product from being used for patented use.
Follow Us
Latest Articles
- Federal Circuit upholds Moderna’s win in COVID vaccine dispute against Alnylam
- Samsung may get UK interim license declaration in ZTE case next week: sole issue is whether UK judiciary has slightest respect for China
- Conditioning interim license on jurisdiction of preference is not acting in “bad faith”: ZTE and Samsung face off in UK hearing
- Now both UPC appellate panels agree on jurisdiction over pre-UPC-start damages
- UPC Roundup (1 week): clarification on arbitrary territory for revocation; first Mannheim anti-antisuit injunction; new BYD case
Looking for something?
